Alnylam Pharmaceuticals, Inc.
ALNY
$220.79
$3.811.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 807.99M | 571.27M | 347.02M | 76.84M | -285.81M |
| Total Depreciation and Amortization | 54.76M | 54.81M | 55.66M | 56.32M | 56.50M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 626.96M | 612.30M | 566.18M | 612.63M | 448.02M |
| Change in Net Operating Assets | -603.82M | -549.39M | -470.70M | -505.85M | -260.16M |
| Cash from Operations | 885.89M | 688.98M | 498.16M | 239.94M | -41.46M |
| Capital Expenditure | -91.95M | -71.56M | -58.70M | -44.50M | -36.55M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 166.89M | 368.58M | 495.03M | 465.08M | -74.22M |
| Cash from Investing | 74.94M | 297.02M | 436.33M | 420.59M | -110.77M |
| Total Debt Issued | 645.69M | 645.69M | 645.69M | 646.37M | -- |
| Total Debt Repaid | -1.19B | -1.19B | -1.19B | -1.14B | -- |
| Issuance of Common Stock | 166.16M | 213.82M | 250.03M | 244.61M | 274.90M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 29.71M | 23.49M | 17.65M | -44.18M | -17.39M |
| Cash from Financing | -351.08M | -309.64M | -279.27M | -293.59M | 257.51M |
| Foreign Exchange rate Adjustments | -16.14M | 13.81M | 34.94M | 23.37M | 39.39M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 593.62M | 690.17M | 690.16M | 390.30M | 144.67M |